Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;9(3):253–262. doi: 10.1111/j.1527-3458.2003.tb00252.x

Development of the Nitrone‐Based Spin Trap Agent NXY‐059 to Treat Acute Ischemic Stroke

Paul A Lapchak 1,2,3,✉, Dalia M Araujo 2
PMCID: PMC6741678  PMID: 14530797

ABSTRACT

The only current FDA‐approved treatment for acute ischemic stroke is thrombolysis with tissue plasminogen activator (tPA). However, there are numerous shortcomings to tPA treatment including an increased incidence of intracerebral hemorrhage (ICH) and a short therapeutic window (3–6 h). In recent years, studies have attempted to identify new therapeutics that might be neuroprotective following ischemic strokes. Free radical scavenging spin trap agents have been proposed as potential candidates for stroke therapy because of the hypothesized role of free radicals in the progression of stroke and ischemia‐induced neurodegeneration. Novel spin trap agents like (disodium‐[(tert‐butylimino) methy1] benzene‐1,3‐disulfonate N‐oxide (NXY‐059) are of particular interest, not only because they are broad‐spectrum nitrone‐based free radical scavengers, but also because of their safety profile in humans. Moreover, the rationale for developing NXY‐059 for the treatment of acute ischemic stroke is further supported by the drug's reported neuroprotective effects. In addition, NXY‐059 may represent a useful adjunct stroke therapy to tPA, since preclinical studies have demonstrated that NXY‐059 increases the therapeutic window for tPA and lowers the occurrence of tPA‐induced ICH.

Keywords: Free radicals, Hemorrhage, Neuroprotection, Nitrone, Oxidative stress Spin trap

Full Text

The Full Text of this article is available as a PDF (83.7 KB).

References

  • 1. Alberts MJ. Diagnosis and treatment of ischemic stroke. Am J Med 1999;106:211–221. [DOI] [PubMed] [Google Scholar]
  • 2. Anderson DE, Yuan XJ, Tseng CM, Rubin LJ, Rosen GM, Tod ML. Nitrone spin‐traps block calcium channels and induce pulmonary artery relaxation independent of free radicals. Biochem Biophys Res Commun 1993;193:878–885. [DOI] [PubMed] [Google Scholar]
  • 3. Anderson KM, Ells G, Bonomi P, Harris JE. Free radical spin traps as adjuncts for the prevention and treatment of disease. Med Hypotheses 1999;52:53–57. [DOI] [PubMed] [Google Scholar]
  • 4. Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator‐induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20:452–457. [DOI] [PubMed] [Google Scholar]
  • 5. Becker DA. Diagnostic and therapeutic applications of azulenyl nitrone spin traps. Cell Mol Life Sci 1999;56:626–633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032–3040. [DOI] [PubMed] [Google Scholar]
  • 7. Chamulitrat W, Jordan SJ, Mason RP, Saito K, Cutler RG. Nitric oxide formation during light‐induced decomposition of phenyl N‐ tert‐butylnitrone. J Biol Chem 1993;268:11520–11527. [PubMed] [Google Scholar]
  • 8. Chen GM, Bray TM, Janzen EG, McCay PB. Excretion, metabolism and tissue distribution of a spin trapping agent, alpha‐phenyl‐N‐tert‐butyl‐nitrone (PBN) in rats. Free Radic Res Commun 1990;9:317–323. [DOI] [PubMed] [Google Scholar]
  • 9. Dehouck MP, Cecchelli R, Richard Green A, Renftel M, Lundquist S. In vitro blood‐brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY‐059 in normoxic, hypoxic and ischemic conditions. Brain Res 2002;955:229–235. [DOI] [PubMed] [Google Scholar]
  • 10. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999;22:391–397. [DOI] [PubMed] [Google Scholar]
  • 11. Edenius C, Strid S, Breitholtz‐Emanuelsson A, Dalin L, Jerling M, Fransson B. NXY‐059, the first nitrone being developed for stroke, is safe and well tolerated in young and elderly healthy volunteers. Cerebrovasc Dis 1999;9:Abs 102. [Google Scholar]
  • 12. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998;18:667–682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222:236–245. [DOI] [PubMed] [Google Scholar]
  • 14. Floyd RA, Hensley K, Jaffery F, et al. Increased oxidative stress brought on by pro‐inflammatory cytokines in neurodegenerative processes and the protective role of nitrone‐based free radical traps. Life Sci 1999;65:1893–1899. [DOI] [PubMed] [Google Scholar]
  • 15. Folbergrova J, Zhao Q, Katsura K, Siesjo BK. N‐tert‐butyl‐alpha‐phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc Natl Acad Sci USA 1995;92:5057–5061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Green AR. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin Exp Pharmacol Physiol 2002;29:1030–1034. [DOI] [PubMed] [Google Scholar]
  • 17. Grotta JC, Alexandrov AV. tPA‐associated reperfusion after acute stroke demonstrated by SPECT. Stroke 1998;29:429–432. [DOI] [PubMed] [Google Scholar]
  • 18. Hahn SM, Lepinski DL, DeLuca AM, Mitchell JB, Pellmar TC. Neurophysiological consequences of nitroxide antioxidants. Can J Physiol Pharmacol 1995;73:399–403. [DOI] [PubMed] [Google Scholar]
  • 19. Elble RJ. Tremor and dopamine agonists. Neurology 2002;58 (Suppl 1): S57–S62. [DOI] [PubMed] [Google Scholar]
  • 20. Hensley K, Carney JM, Stewart CA, Tabatabaie T, Pye Q, Floyd RA. Nitrone‐based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int Rev Neurobiol 1997;40:299–317. [DOI] [PubMed] [Google Scholar]
  • 21. Hensley K, Pye QN, Maidt ML, et al. Interaction of alpha‐phenyl‐N‐tert‐butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 1998;71:2549–2557. [DOI] [PubMed] [Google Scholar]
  • 22. Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST‐E study. MAST‐E Group. Stroke 1999;30:1326–1332. [DOI] [PubMed] [Google Scholar]
  • 23. Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion injury after focal cerebral ischemia: The role of inflammation and the therapeutic horizon. Neurosurgery 1998;43:1382–13 96;discussion 1396–1397. [DOI] [PubMed] [Google Scholar]
  • 24. Kotake Y. Pharmacologic properties of phenyl N‐tert‐butylnitrone. Antioxid Redox Signal 1999;1:481–499. [DOI] [PubMed] [Google Scholar]
  • 25. Kuroda S, Katsura K, Hillered L, Bates TE, Siesjo BK. Delayed treatment with alpha‐phenyl‐N‐tert‐butyl nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat. Neurobiol Dis 1996;3:149–157. [DOI] [PubMed] [Google Scholar]
  • 26. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK. Neuroprotective effects of a novel nitrone, NXY‐059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778–787. [DOI] [PubMed] [Google Scholar]
  • 27. Lapchak PA. Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep 2002;2:38–43. [DOI] [PubMed] [Google Scholar]
  • 28. Lapchak PA. Development of thrombolytic therapy for stroke: A perspective. Exp Opin Invest Drugs 2002;11:1623–1632. [DOI] [PubMed] [Google Scholar]
  • 29. Lapchak PA, Araujo DM. Reducing bleeding complications after thrombolytic therapy for stroke: Clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 2001;15:819–829. [DOI] [PubMed] [Google Scholar]
  • 30. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium‐[(tert‐butylimino)methyl]benzene‐1,3–disulfonate N‐oxide (generic NXY‐059) in a rabbit small clot embolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002;33:1411–1415. [DOI] [PubMed] [Google Scholar]
  • 31. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA. Effects of the spin trap agent disodium‐[tert‐butylimino)methyl]benzene‐1,3‐disulfonate N‐oxide (generic NXY‐059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: Combination studies with tissue plasminogen activator. Stroke 2002;33:1665–1670. [DOI] [PubMed] [Google Scholar]
  • 32. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: A novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002;33:2279–2284. [DOI] [PubMed] [Google Scholar]
  • 33. Lees KR, Sharma AK, Barer D, et al. Tolerability and pharmacokinetics of the nitrone NXY‐059 in patients with acute stroke. Stroke 2001;32:675–680. [DOI] [PubMed] [Google Scholar]
  • 34. Lees KR, Barer D, Ford GA, et al. Tolerability of NXY‐059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482–487. [DOI] [PubMed] [Google Scholar]
  • 35. Lewen A, Skoglosa Y, Clausen F, et al. Paradoxical increase in neuronal DNA fragmentation after neuroprotective free radical scavenger treatment in experimental traumatic brain injury. J Cereb Blood Flow Metab 2001;21:344–350. [DOI] [PubMed] [Google Scholar]
  • 36. Li PA, He QP, Nakamura L, Csiszar K. Free radical spin trap alpha‐phenyl‐N‐tert‐butyl‐nitron inhibits caspase‐3 activation and reduces brain damage following a severe forebrain ischemic injury. Free Radic Biol Med 2001;31:1191–1197. [DOI] [PubMed] [Google Scholar]
  • 37. Maples KR, Ma F, Zhang YK. Comparison of the radical trapping ability of PBN, S‐PPBN and NXY‐059. Free Radic Res 2001;34:417–426. [DOI] [PubMed] [Google Scholar]
  • 38. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY‐059, a free radical‐trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32:190–198. [DOI] [PubMed] [Google Scholar]
  • 39. Milatovic D, Radic Z, Zivin M, Dettbarn WD. Atypical effect of some spin trapping agents: Reversible inhibition of acetylcholinesterase. Free Radic Biol Med 2000;28:597–603. [DOI] [PubMed] [Google Scholar]
  • 40. Mori H, Arai T, Ishii H, et al. Neuroprotective effects of pterin‐6‐aldehyde in gerbil global brain ischemia: Comparison with those of alpha‐phenyl‐N‐tert‐butyl nitrone. Neurosci Lett 1998;241:99–102. [DOI] [PubMed] [Google Scholar]
  • 41. Nakashima M, Niwa M, Iwai T, Uematsu T. Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic Biol Med 1999;26:722–729. [DOI] [PubMed] [Google Scholar]
  • 42. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM. Efficacy of disodium 4‐[(tert‐butylimino)methyl]benzene‐1,3‐disulfonate N‐oxide (NXY‐059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 2001;40:433–439. [DOI] [PubMed] [Google Scholar]
  • 43. Sang H, Wallis GL, Stewart CA, Kotake Y. Expression of cytokines and activation of transcription factors in lipopolysaccharide‐administered rats and their inhibition by phenyl‐N‐tert‐butylnitrone (PBN). Arch Biochem Biophys 1999;363:341–348. [DOI] [PubMed] [Google Scholar]
  • 44. Schulz JB, Matthews RT, Jenkins BG, Brar P, Beal MF. Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. J Cereb Blood Flow Metab 1995;15:948–952. [DOI] [PubMed] [Google Scholar]
  • 45. Siesjö BK, Siesjö P. Mechanisms of secondary brain injury. Eur J Anaesthesiol 1996;13:247–268. [PubMed] [Google Scholar]
  • 46. Siesjö BK, Katsura K, Zhao Q, et al. Mechanisms of secondary brain damage in global and focal ischemia: A speculative synthesis. J Neurotrauma 1995;12:943–956. [DOI] [PubMed] [Google Scholar]
  • 47. Simoons ML. Risk‐benefit of thrombolysis. Cardiol Clin 1995;13:339–345. [PubMed] [Google Scholar]
  • 48. Stewart CA, Hyam K, Wallis G, et al. Phenyl‐N‐tert‐butylnitrone demonstrates broad‐spectrum inhibition of apoptosis‐associated gene expression in endotoxin‐treated rats. Arch Biochem Biophys 1999;365:71–74. [DOI] [PubMed] [Google Scholar]
  • 49. Strid S, Borga O, Edenius C, Jostell KG, Odergren T, Weil A. Pharmacokinetics in renally impaired subjects of NXY‐059, a nitrone‐ based, free‐radical trapping agent developed for the treatment of acute stroke. Eur J Clin Pharmacol 2002;58:409–415. [DOI] [PubMed] [Google Scholar]
  • 50. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY‐059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103–112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Thomas CE, Ku G, Kalyanaraman B. Nitrone spin trap lipophilicity as a determinant for inhibition of low density lipoprotein oxidation and activation of interleukin‐1 beta release from human monocytes. J Lipid Res 1994;35:610–619. [PubMed] [Google Scholar]
  • 52. Thomas CE, Ohlweiler DF, Carr AA, et al. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J Biol Chem 1996;271:3097–3104. [DOI] [PubMed] [Google Scholar]
  • 53. Tsuji M, Inanami O, Kuwabara M. Neuroprotective effect of alpha‐phenyl‐N‐tert‐butylnitrone in gerbil hippocampus is mediated by the mitogen‐activated protein kinase pathway and heat shock proteins. Neurosci Lett 2000;282:41–44. [DOI] [PubMed] [Google Scholar]
  • 54. Vrbjar N, Zollner S, Haseloff RF, Pissarek M, Blasig IE. PBN spin trapping of free radicals in the reperfusion‐injured heart. Limitations for pharmacological investigations. Mol Cell Biochem 1998;186:107–115. [PubMed] [Google Scholar]
  • 55. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997;350:607–614. [DOI] [PubMed] [Google Scholar]
  • 56. Yang Y, Li Q, Shuaib A. Neuroprotection by 2‐h postischemia administration of two free radical scavengers, alpha‐phenyl‐n‐tert‐butyl‐nitrone (PBN) and N‐tert‐buty1‐(2‐ sulfopheny1)‐nitrone (S‐PBN), in rats subjected to focal embolic cerebral ischemia. Exp Neurol 2000;163:39–45. [DOI] [PubMed] [Google Scholar]
  • 57. Yoshimoto T, Kristian T, Hu B, Ouyang YB, Siesjö BK. Effect of NXY‐059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res 2002;932:99–109. [DOI] [PubMed] [Google Scholar]
  • 58. Yue TL, Gu JL, Lysko PG, Cheng HY, Barone FC, Feuerstein G. Neuroprotective effects of phenyl‐t‐butyl‐nitrone in gerbil global brain ischemia and in cultured rat cerebellar neurons. Brain Res 1992;574:193–197. [DOI] [PubMed] [Google Scholar]
  • 59. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM. NXY‐059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001;909:46–50. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES